For the last 20 years, Dr. Steinbach has led an NIH-funded multidisciplinary clinical care and research program supporting immunosuppressed children. His molecular, translational, and clinical research focuses on the pathogenesis, diagnosis and treatment of invasive fungal infections and spans broader efforts with all infections in immunocompromised patients. His laboratory centers on the fungus Aspergillus fumigatus to understand the molecular mechanisms of cellular signal transduction in disease, develop novel fungal-specific molecular targets as therapeutics, devise new diagnostic assays, and conduct phase I-IV clinical trials in children.
Dr. Steinbach founded and is the Director of the International Pediatric Fungal Network, a global consortium of 55 sites dedicated to investigating pediatric invasive fungal infections through multi-center cooperative studies that have led to the first pediatric-specific guidelines for these diseases. He also co-founded and co-Chairs the biennial (2004-2022 to date) international Advances Against Aspergillosis conference. He has co-edited four textbooks, including Aspergillus fumigatus and Aspergillosis, Feigin & Cherry's Textbook of Pediatric Infectious Diseases, the American Academy of Pediatrics Nelson's Pediatric Antimicrobial Therapy, and most recently, the first textbook in a new subfield: Pediatric Transplant and Oncology Infectious Diseases.
All patient satisfaction surveys are submitted by verified patients and families of Arkansas Children's. The star rating is an average of all responses to the provider-related questions by an independent patient satisfaction company. Responses are measured on a scale of 1 to 5 with 5 being the best score. The comments listed reflect the positive experiences submitted by patients and families through the survey process. The comments are not endorsed by and do not necessarily reflect the views or Arkansas Children's.
The National Institutes of Health Awards Arkansas Children’s Research Institute and Children’s Hospital of Philadelphia $9.7 Million for antifungal therapy study.
Because of its benefits, one of the first children in line to get the COVID vaccine is that of infectious disease doctor, Jessica Snowden, M.D. Read her story.